Darwin Global Management, Ltd. Keros Therapeutics, Inc. Transaction History

Darwin Global Management, Ltd.

$827 Million
Q2 2024

A detailed history of Darwin Global Management, Ltd. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Darwin Global Management, Ltd. holds 1,525,902 shares of KROS stock, worth $91.5 Million. This represents 8.43% of its overall portfolio holdings.

Number of Shares

1,525,902

Previous 1,435,950 6.26%

Holding current value

$91.5 Million

Previous $95.1 Million 26.64%

% of portfolio

8.43%

Previous 16.21%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$44.58 - $66.89 $4.01 Million - $6.02 Million	89,952 Added 6.26%	1,525,902 $69.7 Million
Q1 2024 May 15, 2024	BUY	$41.26 - $70.48 $15.5 Million - $26.5 Million	375,523 Added 35.41%	1,435,950 $95.1 Million
Q4 2023 Feb 14, 2024	BUY	$27.12 - $41.05 $28.8 Million - $43.5 Million	1,060,427 New	1,060,427 $42.2 Million
Q1 2023 May 15, 2023	SELL	$41.44 - $59.32 $16.5 Million - $23.6 Million	-397,146 Reduced 92.68%	31,386 $1.34 Million
Q4 2022 Feb 14, 2023	BUY	$39.45 - $51.77 $16.9 Million - $22.2 Million	428,532 New	428,532 $20.6 Million
Q1 2022 May 16, 2022	SELL	$42.12 - $59.36 $4.7 Million - $6.62 Million	-111,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$36.95 - $62.89 $4.12 Million - $7.01 Million	111,500 New	111,500 $6.52 Million
Q3 2021 Nov 15, 2021	SELL	$29.27 - $43.71 $3.05 Million - $4.55 Million	-104,186 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$42.4 - $70.11 $733,477 - $1.21 Million	17,299 Added 19.91%	104,186 $4.43 Million
Q1 2021 May 17, 2021	BUY	$54.0 - $75.28 $4.69 Million - $6.54 Million	86,887 New	86,887 $5.35 Million

Others Institutions Holding KROS

# of Institutions

156

Shares Held

27.5M

Call Options Held

28.7K

Put Options Held

1.8K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.54B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Darwin Global Management, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Darwin Global Management, Ltd. with notifications on news.

Account

Darwin Global Management, Ltd. Keros Therapeutics, Inc. Transaction History